Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Biologic Therapies for Crohn's Disease: Update from the 2009 ACG Meeting.

Literature DB >> 20567545

Biologic Therapies for Crohn's Disease: Update from the 2009 ACG Meeting.

David G Binion¹.

Abstract

Entities: Disease

Year: 2010 PMID： 20567545 PMCID： PMC2886448

Source DB: PubMed Journal: Gastroenterol Hepatol (N Y) ISSN： 1554-7914

× No keyword cloud information.

32 in total

1. Prevalence of penetrating disease and extraintestinal manifestations of Crohn's disease detected with CT enterography.

Authors: David H Bruining; Hassan A Siddiki; Joel G Fletcher; William J Tremaine; William J Sandborn; Edward V Loftus
Journal: Inflamm Bowel Dis Date: 2008-12 Impact factor: 5.325

2. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.

Authors: William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Jean-Frédéric Colombel; Remo Panaccione; Geert D'Haens; Ju Li; Marie R Rosenfeld; Jeffrey D Kent; Paul F Pollack
Journal: Ann Intern Med Date: 2007-04-30 Impact factor: 25.391

3. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

Authors: Stephan R Targan; Brian G Feagan; Richard N Fedorak; Bret A Lashner; Remo Panaccione; Daniel H Present; Martina E Spehlmann; Paul J Rutgeerts; Zsolt Tulassay; Miroslava Volfova; Douglas C Wolf; Chito Hernandez; Jeffrey Bornstein; William J Sandborn
Journal: Gastroenterology Date: 2007-03-21 Impact factor: 22.682

4. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.

Authors: Brian G Feagan; Remo Panaccione; William J Sandborn; Geert R D'Haens; Stefan Schreiber; Paul J Rutgeerts; Edward V Loftus; Kathleen G Lomax; Andrew P Yu; Eric Q Wu; Jingdong Chao; Parvez Mulani
Journal: Gastroenterology Date: 2008-08-03 Impact factor: 22.682

Biologic Therapies for Crohn's Disease: Update from the 2009 ACG Meeting.

1. Prevalence of penetrating disease and extraintestinal manifestations of Crohn's disease detected with CT enterography.

2. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.

3. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

4. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.

Review 5. The genetics and immunopathogenesis of inflammatory bowel disease.

6. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States.

Review 7. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues.

8. Certolizumab pegol for the treatment of Crohn's disease.

9. Maintenance therapy with certolizumab pegol for Crohn's disease.

Review 10. Extraintestinal manifestations of inflammatory bowel disease.

1. Certolizumab pegol for the treatment of Crohn's disease.

Review 2. Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn's disease?

3. Treatment Pathways Leading to Biologic Therapies for Ulcerative Colitis and Crohn's Disease in the United States.